406 related articles for article (PubMed ID: 25540416)
21. Epstein-Barr Virus B Cell Growth Transformation: The Nuclear Events.
Zhao B
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112815
[TBL] [Abstract][Full Text] [Related]
22. EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.
Styles CT; Bazot Q; Parker GA; White RE; Paschos K; Allday MJ
PLoS Biol; 2017 Aug; 15(8):e2001992. PubMed ID: 28771465
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth.
Maruo S; Johannsen E; Illanes D; Cooper A; Kieff E
J Virol; 2003 Oct; 77(19):10437-47. PubMed ID: 12970429
[TBL] [Abstract][Full Text] [Related]
24. The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.
Banerjee S; Lu J; Cai Q; Saha A; Jha HC; Dzeng RK; Robertson ES
PLoS Pathog; 2013; 9(5):e1003314. PubMed ID: 23658517
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.
Waltzer L; Perricaudet M; Sergeant A; Manet E
J Virol; 1996 Sep; 70(9):5909-15. PubMed ID: 8709211
[TBL] [Abstract][Full Text] [Related]
26. An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.
Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Bristol JA; Ma S; Ranheim EA; Gumperz J; Johannsen EC; Kenney SC
PLoS Pathog; 2018 Aug; 14(8):e1007221. PubMed ID: 30125329
[TBL] [Abstract][Full Text] [Related]
27. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
28. Core binding factor (CBF) is required for Epstein-Barr virus EBNA3 proteins to regulate target gene expression.
Paschos K; Bazot Q; Ho G; Parker GA; Lees J; Barton G; Allday MJ
Nucleic Acids Res; 2017 Mar; 45(5):2368-2383. PubMed ID: 27903901
[TBL] [Abstract][Full Text] [Related]
29. RUNX super-enhancer control through the Notch pathway by Epstein-Barr virus transcription factors regulates B cell growth.
Gunnell A; Webb HM; Wood CD; McClellan MJ; Wichaidit B; Kempkes B; Jenner RG; Osborne C; Farrell PJ; West MJ
Nucleic Acids Res; 2016 Jun; 44(10):4636-50. PubMed ID: 26883634
[TBL] [Abstract][Full Text] [Related]
30. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr Virus Nuclear Antigen 3C Facilitates Cell Proliferation by Regulating Cyclin D2.
Pei Y; Singh RK; Shukla SK; Lang F; Zhang S; Robertson ES
J Virol; 2018 Sep; 92(18):. PubMed ID: 29997218
[TBL] [Abstract][Full Text] [Related]
32. EBV persistence without its EBNA3A and 3C oncogenes in vivo.
Murer A; McHugh D; Caduff N; Kalchschmidt J; Barros M; Zbinden A; Capaul R; Niedobitek G; Allday M; Chijioke O; Münz C
PLoS Pathog; 2018 Apr; 14(4):e1007039. PubMed ID: 29709016
[TBL] [Abstract][Full Text] [Related]
33. EBNA2 and activated Notch induce expression of BATF.
Johansen LM; Deppmann CD; Erickson KD; Coffin WF; Thornton TM; Humphrey SE; Martin JM; Taparowsky EJ
J Virol; 2003 May; 77(10):6029-40. PubMed ID: 12719594
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical.
Maruo S; Johannsen E; Illanes D; Cooper A; Zhao B; Kieff E
J Virol; 2005 Aug; 79(16):10171-9. PubMed ID: 16051810
[TBL] [Abstract][Full Text] [Related]
35. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity.
Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors.
Ma Y; Walsh MJ; Bernhardt K; Ashbaugh CW; Trudeau SJ; Ashbaugh IY; Jiang S; Jiang C; Zhao B; Root DE; Doench JG; Gewurz BE
Cell Host Microbe; 2017 May; 21(5):580-591.e7. PubMed ID: 28494239
[TBL] [Abstract][Full Text] [Related]
37. EBNA2 and Its Coactivator EBNA-LP.
Kempkes B; Ling PD
Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
[TBL] [Abstract][Full Text] [Related]
38. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
Yoo L; Speck SH
J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
[TBL] [Abstract][Full Text] [Related]
39. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa).
Robertson ES; Lin J; Kieff E
J Virol; 1996 May; 70(5):3068-74. PubMed ID: 8627785
[TBL] [Abstract][Full Text] [Related]
40. Conditional expression of a dominant-negative form of Epstein-Barr virus (EBV) nuclear antigen EBNALP inhibits EBV-positive lymphoblastoid cell growth.
Harada S; Saijo M
Arch Virol; 2020 Feb; 165(2):313-320. PubMed ID: 31813023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]